Active Diabetes, Hormones & Metabolism Infection & Immunity

Targeting the circadian clock to restore hepatitis B T-cell immunity

In plain English

AI plain-English summary

The circadian clock inside liver cells may be sabotaging the immune system's ability to fight hepatitis B virus. Hepatitis B infects only the human liver and remains a major health problem worldwide. Current antivirals reduce the viral burden but are not curative and do not remove the risk of liver cancer. Chronic hepatitis B is associated with poor anti-viral T-cell immunity that fails to control viral replication. Researchers recently discovered a disruption of clock genes in the liver of hepatitis B patients, which they hypothesise contributes to the poor T-cell response in the infected liver. Their data suggest that manipulating circadian pathways with drugs can enhance the function of hepatitis B-specific T-cells. If this research succeeds, it could identify novel therapeutic opportunities for restoring T-cell immunity and improve the efficacy of hepatitis B therapeutic vaccines. In a broader context, understanding how clocks communicate between tissue and local immunity could apply to many other pathogens. This is primarily fundamental science exploring how the body's daily rhythms control immune responses in the liver, but it directly targets a specific clinical need: curative treatments for chronic hepatitis B.

View original technical description
Circadian rhythms regulate changes in physiological and metabolic processes which allow organisms on earth to respond to daily environmental demands and pathogenic exposure. Host innate and adaptive immune responses are circadian regulated and influence susceptibility to viral infection and response to vaccines. In recent years, scientists have discovered the genetic machinery that underpins the daily cycling of the circadian clock that operates in individual cells. Furthermore, scientists uncovered communications between circadian clocks of different cell types within an organ, and that genetically perturbing the clock in the hepatocytes can impact the clocks in their neighbouring immune cells. Therefore, there is reason to believe that the circadian clock controls immunity within the liver which is essential for viral protection. Hepatitis B virus (HBV) only infects the human liver and remains a major health problem with >270 million chronic infections and 880,000 deaths/year worldwide from liver disease including cirrhosis and cancer. Current antivirals reduce the viral burden but are not curative and do not remove the risk of liver cancer. Chronic hepatitis B is associated with poor anti-viral T-cell immunity that fails to control viral replication. Therefore, curative treatments are desperately needed, and understanding what causes these T-cell defects could aid the design and evaluation of curative therapies. We recently discovered a disruption of clock genes in the liver of HBV patients, which I hypothesise contributes to the poor T-cell response in the infected liver. Importantly, our recent data suggest that manipulation of circadian pathways by drugs can enhance the function of HBV-specific T-cells in CHB patients. Therefore by studying how the circadian system regulates T-cell immunity in the infected liver and how the time of day affects HBV vaccine efficacy, we will identify novel therapeutic opportunities for T-cell restoration and improve the efficacy of HBV therapeutic vaccines. In a broader context, knowledge of the communication of clocks between tissue and local immunity will be applicable to many other pathogens.

View the original record at the funder ↗

Researchers

Alan Xiaodong Zhuang (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Harnessing tissue-resident CD8 T cells to manipulate hepatic immunity
Redirecting T cells to overcome tolerance in chronic HBV infection
Metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells
Understanding host factors that regulate the hepatitis B viral epigenome
Immune (dys-)regulation by the PD-1/PD-L checkpoint pathway in chronic liver disease

Original classification

Fellowship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.